Evolution of calcium antagonists: past, present, and future

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Calcium antagonists evolved from fast-acting vasodilators to agents with smooth onset and long duration.
• Early calcium antagonists caused hemodynamic adverse effects; newer agents offer improved tolerability.
• Diabetes exacerbates cardiovascular risk, necessitating multiple drug therapy for hypertensive diabetic patients.

Purpose of the Study:

• To evaluate the evolution of calcium antagonists in hypertension management.
• To assess the benefits of calcium antagonists in diabetic hypertensive patients.
• To compare the tolerability profiles of older and newer calcium antagonists, focusing on pedal edema.

Main Methods:

• Review of clinical trial data, including Systolic Hypertension in Europe and Systolic Hypertension in China trials.
• Analysis of hemodynamic effects and adverse event profiles of different calcium antagonist classes.
• Comparison of efficacy and side effect incidence between older and newer dihydropyridine calcium antagonists.

Main Results:

• Calcium antagonists demonstrated significant antihypertensive properties and improved tolerability in newer agents.
• Diabetic subgroups in major trials showed over 50% reduction in total mortality with calcium antagonists.
• Pedal edema, a common side effect of older dihydropyridines, is dose-dependent and reduced in newer agents.

Conclusions:

• Newer calcium antagonists maintain antihypertensive efficacy with an improved tolerability profile, notably reduced pedal edema.
• Calcium antagonists are valuable in managing hypertension in diabetic patients, contributing to reduced mortality.
• The evolution of calcium antagonists provides safer and more effective treatment options for cardiovascular disease.